RecruitingMetastatic Colorectal Cancer

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Eligible age

18+ yrs

Accepts

All genders

Locations

14 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

Sponsor: Amgen

You may qualify if…

✓ Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay.
✓ Central laboratory detection of KRAS p.G12C mutation.
✓ Measurable metastatic disease per RECIST v1.1 criteria.
✓ Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.
✓ Adequate organ function.

You may not qualify if…

✕ Active, untreated brain metastases.
✕ Leptomeningeal disease
✕ Previous treatment with a KRAS p.G12C inhibitor
✕ History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline CT scan